Inyx, Inc. (IYXI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Inyx, Inc. (IYXI). Inyx, Inc. is a specialty pharmaceutical company focused on developing and manufacturing prescription and over-the-counter products. Sector: Healthcare.
Last analyzed: Mar 17, 2026IYXI: 1/1 perspectives are bearish.
Inyx, Inc. (IYXI) Healthcare & Pipeline Overview
Inyx, Inc. is a specialty pharmaceutical company operating in the US, Canada, and Europe, focusing on developing and manufacturing prescription and over-the-counter products, particularly in inhalation-therapy drug delivery. The company's product pipeline includes generic versions of respiratory inhalants and novel barrier technologies for topical applications.
What Is the Investment Thesis for IYXI?
Inyx, Inc. presents a speculative investment opportunity in the specialty pharmaceutical sector. The company's focus on niche drug delivery systems, such as inhalation therapies and topical applications, could provide growth potential. However, its OTC market listing and negative profitability raise concerns. Key value drivers include successful development and commercialization of its proprietary products, particularly generic versions of respiratory inhalants. The company's high gross margin of 93.0% suggests pricing power, but its negative profit margin of -6.3% indicates high operating costs. Investors should closely monitor the company's ability to secure funding, navigate regulatory hurdles, and achieve profitability. The company's beta of -91.80 suggests an inverse correlation with the market, which may offer diversification benefits but also indicates unique risk factors.
Based on FMP financials and quantitative analysis
IYXI Key Highlights
- Gross margin of 93.0% indicates potential pricing power in its niche product offerings.
- Focus on inhalation-therapy drug delivery devices and methods provides specialization in a growing market.
- Negative profit margin of -6.3% highlights challenges in achieving profitability.
- Beta of -91.80 suggests an inverse correlation with the market, indicating unique risk factors.
- Operates in the United States, Canada, and Europe, providing geographic diversification.
Who Are IYXI's Competitors?
Who Are IYXI's Competitors?
IYXI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CALA Calithera Biosciences, Inc. | $0.00 | -66.67% | 3K | 39 |
| INND InnerScope Hearing Technologies, Inc. | $0.00 | +0.00% | 613 | — |
| MJNE MJ Holdings, Inc. | $0.00 | +0.00% | 12K | 57 |
| MSGP MedSmart Group Inc. | $0.00 | +0.00% | 31K | — |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.33 | -0.23% | 817M | 68 |
| OMHE Omni Health, Inc. | $0.00 | +0.00% | 29K | 63 |
| ONC BeOne Medicines Ltd. | $293.60 | +0.11% | 32B | 61 |
| WLCGF Welcia Holdings Co., Ltd. | $16.41 | +0.00% | $3.42B | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IYXI's Key Strengths?
- Specialized expertise in drug delivery systems.
- Proprietary products under development.
- Manufacturing capabilities for various pharmaceutical products.
- Geographic diversification across the United States, Canada, and Europe.
What Are IYXI's Weaknesses?
- Negative profit margin.
- OTC market listing.
- Limited financial resources.
- Dependence on successful development and commercialization of new products.
What Could Drive IYXI Stock Higher?
- Regulatory approval of generic respiratory inhalants by 2027 could drive revenue growth.
- Commercialization of novel barrier technologies for topical applications by 2027 may increase market share.
- Expansion of specialty pharmaceutical consulting services to generate revenue and build relationships.
- Strategic partnerships with other pharmaceutical companies to expand market reach.
- Positive clinical trial results for anti-inflammatory nasal pumps by 2026 could increase investor confidence.
What Are the Key Risks for IYXI?
- Intense competition from larger pharmaceutical companies could limit market share.
- Stringent regulatory requirements may delay or prevent product approvals.
- Patent expirations and generic competition could erode pricing power.
- Product liability risks associated with pharmaceutical products.
- Limited financial resources may hinder growth initiatives.
What Are the Growth Opportunities for IYXI?
- Expansion of Generic Respiratory Inhalants: The market for generic respiratory inhalants is expanding due to the expiration of patents on branded drugs. Inyx's development of generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants positions it to capture a share of this growing market. Successful development and regulatory approval could lead to significant revenue growth by 2028.
- Novel Barrier Technologies for Topical Applications: Inyx's focus on wound irrigation and cleansing sprays that utilize novel barrier technologies offers growth potential in the topical drug delivery market. These technologies can provide improved efficacy and patient compliance, creating a competitive advantage. Market penetration could increase significantly by 2027 with successful clinical trials and commercialization.
- Specialty Pharmaceutical Consulting Services: Inyx provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market. This service offering can generate revenue and build relationships with potential partners. Expanding the consulting business could provide a stable revenue stream and enhance the company's reputation within the industry by 2026.
- Geographic Expansion in Europe: Inyx operates in the United States, Canada, and Europe. Expanding its market presence in Europe, particularly in countries with favorable regulatory environments and growing healthcare spending, could drive revenue growth. This expansion could be realized by 2028 through strategic partnerships and targeted marketing efforts.
- Development of Anti-Inflammatory Nasal Pumps: Inyx is developing anti-inflammatory nasal pumps, which target the growing market for allergy and respiratory treatments. Successful development and commercialization of these products could provide a significant revenue stream. Market introduction is anticipated by 2027, pending regulatory approvals and clinical trial outcomes.
What Opportunities Does IYXI Have?
- Expansion of generic respiratory inhalant market.
- Growing demand for novel drug delivery technologies.
- Increasing healthcare spending in Europe.
- Potential partnerships with other pharmaceutical companies.
What Threats Does IYXI Face?
- Intense competition from larger pharmaceutical companies.
- Stringent regulatory requirements.
- Patent expirations and generic competition.
- Product liability risks.
What Are IYXI's Competitive Advantages?
- Specialized expertise in inhalation-therapy drug delivery devices.
- Proprietary products under development, including generic versions of respiratory inhalants.
- Manufacturing capabilities for hydrocarbon aerosols, metered dose inhalers, and other drug delivery systems.
- Established presence in the United States, Canada, and Europe.
What Does IYXI Do?
Inyx, Inc., established in 2000 and headquartered in New York City, operates as a specialty pharmaceutical company through its wholly-owned subsidiaries. The company develops and manufactures a range of prescription and over-the-counter pharmaceutical products, catering to markets in the United States, Canada, and Europe. Its core business revolves around manufacturing hydrocarbon aerosols, a delivery system for dermatological and topical drug applications, metered dose inhalers for respiratory conditions, dry powdered inhalers, metered dose nasal and throat pumps, sprays, and sterile salines and injectables. Inyx focuses its research and development activities on inhalation-therapy drug delivery devices and methods, as well as generic prescription and over-the-counter aerosol pharmaceutical products for respiratory, allergy, dermatological, topical, and cardiovascular applications. The company's proprietary products under development include generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants, nonCFC propelled oral sprays for cardiovascular ailments, wound irrigation, and cleansing sprays that utilize novel barrier technologies, and anti-inflammatory nasal pumps. In addition to its product development and manufacturing activities, Inyx provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market, leveraging its expertise in drug delivery systems and pharmaceutical formulations.
What Products and Services Does IYXI Offer?
- Develops and manufactures prescription pharmaceutical products.
- Develops and manufactures over-the-counter pharmaceutical products.
- Manufactures hydrocarbon aerosols for dermatological and topical drug applications.
- Produces metered dose inhalers for respiratory conditions.
- Manufactures dry powdered inhalers for respiratory ailments.
- Develops metered dose nasal and throat pumps and sprays.
- Manufactures sterile salines and injectables.
- Provides specialty pharmaceutical development and manufacturing consulting services.
How Does IYXI Make Money?
- Develops and manufactures pharmaceutical products.
- Sells prescription and over-the-counter drugs through distribution channels.
- Generates revenue through product sales in the United States, Canada, and Europe.
- Provides consulting services to other healthcare companies.
What Industry Does IYXI Operate In?
Inyx, Inc. operates within the medical pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and rapid technological advancements. The market for drug delivery systems, particularly inhalation therapies, is experiencing growth due to the increasing prevalence of respiratory diseases and the demand for more efficient drug administration methods. Inyx competes with both large pharmaceutical companies and smaller specialty firms. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively commercialize its products in a competitive landscape.
Who Are IYXI's Key Customers?
- Pharmacies and retail stores that sell over-the-counter medications.
- Hospitals and clinics that use prescription medications.
- Patients who purchase prescription and over-the-counter drugs.
- Other pharmaceutical companies seeking development and manufacturing consulting services.
IYXI Financials
IYXI Latest News
No recent news available for IYXI.
IYXI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IYXI.
Price Targets
Wall Street price target analysis for IYXI.
IYXI MoonshotScore
What does this score mean?
The MoonshotScore rates IYXI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Steven Handley
CEO
Steven Handley serves as the CEO of Inyx, Inc., overseeing the company's operations and strategic direction. His background includes experience in managing teams and resources within the pharmaceutical industry. He is responsible for guiding the company's research and development efforts, manufacturing processes, and commercialization strategies. His leadership is critical to the company's ability to navigate the competitive pharmaceutical landscape and achieve its growth objectives.
Track Record: Under Steven Handley's leadership, Inyx, Inc. has focused on developing and manufacturing specialized pharmaceutical products, including inhalation therapies and topical applications. Key milestones include the advancement of generic respiratory inhalants and the development of novel barrier technologies. His strategic decisions aim to position the company for growth in niche markets within the pharmaceutical industry.
IYXI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Inyx, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase investment risk.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Limited regulatory oversight and investor protection.
- Going concern risk due to financial instability.
- Verify the availability of current and historical financial statements.
- Assess the company's management team and their track record.
- Review the company's business plan and growth strategy.
- Evaluate the company's competitive position and market opportunities.
- Determine the company's capital structure and debt levels.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Focus on specialty pharmaceutical products and consulting services.
- Operations in the United States, Canada, and Europe.
- Development of proprietary products and drug delivery systems.
- Management team with experience in the pharmaceutical industry.
What Investors Ask About Inyx, Inc. (IYXI) — Healthcare
What does Inyx, Inc. do?
Inyx, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter pharmaceutical products. The company focuses on niche drug delivery systems, including hydrocarbon aerosols, metered dose inhalers, and nasal pumps. Inyx operates in the United States, Canada, and Europe, providing both pharmaceutical products and consulting services to the healthcare market. The company's strategy revolves around developing generic versions of existing drugs and innovating in drug delivery technologies.
What do analysts say about IYXI stock?
AI analysis is currently pending for IYXI. As an OTC-listed company, Inyx, Inc. may not have extensive analyst coverage. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors. Key valuation metrics to consider include revenue growth, gross margin, and profitability. Investors should also monitor the company's progress in developing and commercializing its proprietary products.
What are the main risks for IYXI?
The main risks for Inyx, Inc. include intense competition from larger pharmaceutical companies, stringent regulatory requirements, and the potential for product liability claims. As an OTC-listed company, Inyx faces additional risks related to limited financial disclosure, low trading volume, and potential price manipulation. The company's success depends on its ability to secure regulatory approvals, effectively commercialize its products, and maintain adequate financial resources. Investors should carefully consider these risks before investing in IYXI.
What are the key factors to evaluate for IYXI?
Evaluating IYXI involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Specialized expertise in drug delivery systems. Primary risk to monitor: Intense competition from larger pharmaceutical companies could limit market share. This is not financial advice.
How frequently does IYXI data refresh on this page?
IYXI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IYXI's recent stock price performance?
Recent price movement in Inyx, Inc. (IYXI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in drug delivery systems. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IYXI overvalued or undervalued right now?
Determining whether Inyx, Inc. (IYXI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IYXI?
Before investing in Inyx, Inc. (IYXI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to the company's OTC listing.
- AI analysis is pending and may provide further insights.